heart iconheart icon
Share
Products & Operating Company
Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®

Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (nesiritide), a prescription medication for patients with heart failure.

As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetic Act, and agreed to pay an $85 million fine.

Scios acknowledges that NATRECOR® was misbranded and used in a way not approved by the U.S. Food and Drug Administration because its labeling lacked adequate directions for that use, but denies any wrongful intent in connection with this plea.

###

Contact:
Media:
Shaun Mickus                                                
Office: (908) 927-2416                                  
smickus@its.jnj.com

Bill Foster
Cell: (908) 392-6057
wfoster@its.jnj.com